Form 4: Vertex Pharma Exec Sells Shares Under 10b5-1 Plan

Jonathan Biller, Executive Vice President and Chief Legal Officer at Vertex Pharmaceuticals, sold 347 shares of common stock for $449 per share under a pre-arranged trading plan.

Summary

• Jonathan Biller, EVP and Chief Legal Officer of Vertex Pharmaceuticals Inc. (VRTX), reported a transaction involving the company's common stock.
• On December 3, 2025, Mr. Biller disposed of 347 shares of common stock.
• The shares were sold at a price of $449 per share.
• This transaction was executed pursuant to a company-approved Rule 10b5-1 trading plan, which was established on February 24, 2025.
• Following this transaction, Mr. Biller beneficially owns 15,306 shares of Vertex Pharmaceuticals common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine insider sale executed under a pre-arranged 10b5-1 trading plan, which typically does not reflect new sentiment on the company's prospects or operational performance. It is generally considered a neutral event.

Future Outlook

NA

Industry Context

This filing reports a routine insider transaction and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-planned insider sale for personal financial management, not indicative of a change in company fundamentals or outlook.

Key Dates

Keywords

Vertex Pharmaceuticals, VRTX, Insider Trading, Form 4, Stock Sale, Jonathan Biller, Executive Compensation, Rule 10b5-1